Women in England with Incurable Breast Cancer to Get Life-Extending Drug on NHS

The National Institute for Health and Care Excellence (Nice) has finally recommended that the NHS cover a life-extending treatment for thousands of women in England living with incurable breast cancer. Enhertu, a targeted therapy developed by AstraZeneca and Daiichi Sankyo, will now be available to about 1,000 patients per year who have seen their cancer progress despite standard chemotherapy.

This breakthrough is the culmination of two years of tireless campaigning by Breast Cancer Now, cancer specialists, and women with HER2-low advanced breast cancer. Claire Rowney, chief executive of Breast Cancer Now, hailed this “momentous day” as a testament to determination and perseverance in the face of seemingly insurmountable obstacles.

Nice’s decision follows significant changes to its framework, which now allows for more flexible pricing negotiations. This newfound freedom has enabled the agency to secure a commercial solution with the pharmaceutical firms involved. While details surrounding the price have not been disclosed, it is clear that Nice has agreed to pay more than initially anticipated – a willingness that highlights the growing pressure on healthcare systems worldwide to provide cutting-edge treatments.

Enhertu’s clinical trial results are nothing short of remarkable: patients who received the treatment experienced almost double the median progression-free survival compared to those undergoing standard chemotherapy. This life-extending benefit is crucial for women facing secondary breast cancer, as it not only improves their quality of life but also buys them precious time with loved ones.

The decision has significant implications beyond England’s borders. Yvette Cooper, the health secretary, pointed out that this recommendation is a direct result of changes made to Nice’s framework under the UK-US pharmaceutical partnership. This collaboration will undoubtedly lead to more innovative treatments being made available across the UK – and potentially beyond its shores.

However, questions remain regarding the true cost of this life-extending treatment. While Enhertu may have been deemed too expensive by Nice just two years ago, it is unclear whether the pharmaceutical firms have reciprocated by reducing their price demands. Transparency in these negotiations is essential to ensure that the NHS’s increased spending on Enhertu does not come at the expense of other critical healthcare services.

Scotland has already seen the benefits of Enhertu, with thousands of patients benefiting from this treatment since December 2023. With Nice’s recommendation now set to open doors for England, Wales, and Northern Ireland, it is essential that these governments prioritize swift implementation and make similar arrangements to ensure seamless access to life-extending treatments.

The Enhertu saga serves as a stark reminder of the delicate balance between innovation in healthcare and affordability. Policymakers must remain vigilant about ensuring that cutting-edge treatments do not exacerbate existing health disparities or strain already overburdened healthcare systems.

Breast Cancer Now’s unwavering advocacy has brought us to this momentous day – and we must now work together to ensure that Enhertu becomes a lifeline for thousands more women in need. The decision to cover Enhertu is not merely a triumph for individual lives saved but also a testament to the power of collaboration between governments, charities, and healthcare professionals.

As we celebrate this hard-won victory, it is essential to recognize the significant work still ahead: guaranteeing access to life-extending treatments while safeguarding the long-term sustainability of our public healthcare systems.